Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
This license will enable Abbott to enhance access to this novel therapy to more patients across India
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
